SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

iBio, Inc. (IBIO)

Add IBIO Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/25/2016 5:43:08 AM - Followers: 232 - Board type: Free - Posts Today: 0



About us

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch™ platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:
  • Ability to synthesize complex proteins at which other systems have failed
    Simplicity, scalability and flexibility
    Reduced capital investment
    Lower operating costs
    Surge capacity
    Rapid production times – gene sequence to factory-scale protein harvest
    Eliminates the need of bioreactors
    Low risk of contamination by animal pathogens

iBio has a strong IP/technology portfolio and has been well established by more than nine years of applications development and $100 million in funding. Our current pipeline includes:

Monoclonal antibodies
Interferons & cytokines
Enzymes for replacement therapy
Plasma-derived proteins
Growth factors
Protease inhibitors
Clotting factors


The iBioLaunch™ platform is a  proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.  The plants are easily and reliably scaled-up in low cost, controlled growth facilities to produce large amounts of recombinant protein in the plant biomass.  The technology is highly flexible having the capability to produce both biotherapeutics and vaccines. Advantages of the whole plant approach include lower operating and capital expenses compared to protein production using engineered microbial or animal cells in bioreactors. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required.  Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed.

The iBioLaunch technology platform addresses several multi-billion dollar markets.  Its applicability to a broad range of product classes enables iBio to target global commercial collaborations in high-growth markets such as orphan biologics ($54.6 billion in 2009), biosimilars/bio-betters (~$80 billion worth of biologics sales will be susceptible to biosimilar competition, by 2013) and new proprietary biologics. The speed and superior economic scalability of the iBioLaunch™ technology make it the ideal platform for new personalized therapeutics as well as for vaccines ($32 billion in 2013).

Our technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.




iBio’s business strategy is to broadly participate in the markets that the iBioLaunchTM platform addresses. We will establish partnerships through product collaborations and platform licensing arrangements. iBio is well-positioned to facilitate the advanced development of products based on the iBioLaunch platform or  to assist in the turn-key implementation of the iBioLaunch technology by our partners.

We have developed a pipeline of clinical and phase I-ready products that use the iBioLaunch platform across various classes and diseases.

iBio offers collaborations with biotechnology and pharmaceutical companies through:

Out-licensing our pipeline of products produced with the iBioLaunch platform
Partnering our technology for exploratory, research or validation studies
Out-licensing the iBioLaunch platform for the production of biotherapeutics and vaccines

For additional information, please contact:

Douglas Hicks
Vice-President, Business Development
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IBIO News: Annual Report (10-k) 10/13/2016 04:07:20 PM
IBIO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 09/28/2016 04:05:06 PM
IBIO News: Quarterly Report (10-q) 05/23/2016 04:46:47 PM
IBIO News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/16/2016 04:56:32 PM
#15262 errett 10/25/16 05:43:08 AM
#15261   SOURCE: iBio, Inc. September 29, 2016 08:30 ET NEW YORK, TORO 09/29/16 09:19:59 AM
#15260   SOURCE: iBio, Inc. ? September 29, 2016 08:30 ET iBio Proprietary TORO 09/29/16 08:47:51 AM
#15259   Harmsen---as of 03/16----$17.6 million in cash from sale errett 09/13/16 12:19:44 PM
#15258   How many cash has the company?Thank you harmsen 09/13/16 06:49:17 AM
#15257   IBIO bullish 0.5921 stocktrademan 09/02/16 04:48:53 PM
#15256   IBIO will one day be a hundred dollar stock. Top Penny 08/19/16 03:02:30 PM
#15255 errett 08/12/16 09:19:34 AM
#15254   Good News: errett 08/05/16 11:09:08 AM
#15253   Keep watching the turn will come. biowatcher 07/26/16 03:05:44 AM
#15252   I'm not seeing anything but downward pressure. Investor 35 07/25/16 07:52:44 PM
#15251   Nothing but blue skies do I see....soon! biowatcher 07/21/16 04:32:08 PM
#15250   Sentiment for Ibio Inc (NYSEMKT:IBIO) errett 07/15/16 06:47:34 AM
#15249   Here is all the dd for this stock: longhorn4lif 07/08/16 10:17:01 PM
#15248   sold out. ash111 07/08/16 02:50:09 PM
#15247   what catalysts could drive pps up? ash111 07/08/16 11:10:09 AM
#15246   official:iBio, Inc. Receives FDA Orphan Drug Designation for ash111 07/05/16 03:00:00 PM
#15245   iBio, Inc. Receives FDA Orphan Drug Designation for ash111 07/05/16 02:17:11 PM
#15244   .60 to .65 as been great support and longhorn4lif 07/01/16 10:08:26 AM
#15243   Thank you.on watch ash111 07/01/16 06:02:24 AM
#15242   PR & newswire tomorrow for FDA news? remind2 06/30/16 09:25:11 PM
#15241   Designated orphan status....not approved longhorn4lif 06/30/16 06:59:05 PM
#15240   you meant this ? ash111 06/30/16 03:00:07 PM
#15239   Smart folks loading! longhorn4lif 06/30/16 01:53:30 PM
#15238   IBIO: FDA approved Orphan Drug Status 6/27/16. No remind2 06/30/16 09:46:33 AM
#15237   Top Penny, it was a very strong day KobeF 06/15/16 04:09:08 PM
#15236   Yea i saw the patent want the news.....thats longhorn4lif 06/15/16 08:00:51 AM
#15235   Fibrosis patent news is out. IBIO to announce Lucathewolf 06/15/16 06:37:59 AM
#15234   Very good day....maybe gets some fibrosis news tomorrow! longhorn4lif 06/14/16 07:39:55 PM
#15233   Yep and its a good source longhorn4lif 06/10/16 09:16:29 AM
#15232   I was just kidding with you, either way Blue Sky Basin 06/10/16 09:13:04 AM
#15231   Nice find.....i was so excited after reading i longhorn4lif 06/10/16 08:41:14 AM
#15230   Lol sorry didny even see it longhorn4lif 06/10/16 08:38:09 AM
#15229   Lol I guess you didn't like my link :) Blue Sky Basin 06/10/16 08:36:15 AM
#15227 Blue Sky Basin 06/10/16 07:50:45 AM
#15226   You're on to it. I just backed Blue Sky Basin 06/09/16 04:16:43 PM
#15225   So many big collaborations here....huge long term play longhorn4lif 06/09/16 12:58:03 PM
#15224 longhorn4lif 06/09/16 12:30:18 PM
#15223   Besides just the ibio cmo and cash on longhorn4lif 06/09/16 08:39:00 AM
#15222   things like what ...what you expect ? bernard23 06/08/16 03:01:56 PM
#15221   In with you guys.....looks like some big things longhorn4lif 06/07/16 11:12:43 AM
#15220   So to me it seems as if Dart Blue Sky Basin 05/17/16 12:56:05 PM
#15219   IBIO ~ I love how under the radar Top Penny 05/09/16 12:52:50 PM
#15218 carolinacoast 05/05/16 09:44:16 PM
#15217   huge insider buy carolinacoast 05/05/16 09:42:51 PM
#15216,+Inc.+(IBIO),+Eastern+Capital+E carolinacoast 05/05/16 09:42:09 PM
#15215   IBIO ~ You're a bit misinformed when it Top Penny 05/05/16 05:02:54 PM
#15214   Yeah, maybe after a couple reverse splits. You're ClayTrader 05/05/16 04:42:35 PM
#15213   IBIO ~ Your going to sell yourself short Top Penny 05/05/16 04:41:19 PM
#15212   Sure it is. There are many ways to ClayTrader 05/05/16 04:37:40 PM